Physician

Tyler William Snedden, M.D.

According to 2025 Medicare claims, Tyler Snedden, M.D. (NPI: 1780002758) practices hematology/oncology in the Waco, TX market, with the plurality of this provider's patient population coming from Mc Lennan, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76712-2452. Snedden is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Snedden's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 421 traditional Medicare patients, billed 70,012 HCPCS/CPT codes, and received $1,025,189 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,398 prescription claims across 191 beneficiaries totaling $2,832,424 in drug costs, led by Brukinsa (Zanubrutinib). Open Payments data shows 35 records totaling $400,971. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $493,804 and ending at $1,025,189. Concurrently, Part D prescription costs have risen steadily, from $28,524 to $2,832,424. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	246	35,667	$493,804
2021	394	58,786	$595,571
2022	404	79,561	$1,011,765
2023	388	59,983	$769,751
2024	421	70,012	$1,025,189

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	36	190	$28,524
2016	34	255	$37,851
2017	37	247	$43,728
2018	11	39	$5,377
2019	N/R	N/R	N/R
2020	26	67	$290,668
2021	106	635	$870,063
2022	124	844	$1,515,413
2023	152	1,026	$1,650,383
2024	191	1,398	$2,832,424

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	312	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	149	261	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	75	252	$12
36415	Insertion of needle into vein for collection of blood sample	224	849	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	222	785	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	62	1,860	$804,316
Revlimid	Lenalidomide	29	812	$678,576
Jakafi	Ruxolitinib Phosphate	23	690	$383,044
Nubeqa	Darolutamide	14	420	$191,002
Abiraterone Acetate	Abiraterone Acetate	27	810	$49,280

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	31	$694	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$400,278	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tyler William Snedden, M.D.?

Tedicare shows public-source Medicare data for Tyler William Snedden, M.D. (NPI 1780002758), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tyler William Snedden, M.D. have ACO affiliation data?

Tyler William Snedden, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Tyler William Snedden, M.D.?

Tyler William Snedden, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Tyler William Snedden, M.D. have Open Payments data?

Tyler William Snedden, M.D. has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.